Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$1.00 0.00 (0.00%)
As of 08/28/2025

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$1.00
$1.00
50-Day Range
$0.00
$1.80
52-Week Range
$0.00
$7.50
Volume
20 shs
Average Volume
7,109 shs
Market Capitalization
$4.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orgenesis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

ORGS MarketRank™: 

Orgenesis scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Orgenesis.

  • Percentage of Shares Shorted

    0.37% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently increased by 104.94%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Orgenesis does not currently pay a dividend.

  • Dividend Growth

    Orgenesis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.37% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently increased by 104.94%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Orgenesis has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Orgenesis this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Orgenesis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.66% of the stock of Orgenesis is held by insiders.

  • Percentage Held by Institutions

    Only 22.56% of the stock of Orgenesis is held by institutions.

  • Read more about Orgenesis' insider trading history.
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORGS Stock News Headlines

Orgenesis Director Ashish Nanda Resigns
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Orgenesis Delays Filing of Quarterly Report
Orgenesis secures $5M equity investment from Williamsburg Venture
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $1.89 on January 1st, 2025. Since then, ORGS shares have decreased by 47.1% and is now trading at $1.00.

Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The company earned $6.98 million during the quarter.

Orgenesis's stock reverse split before market open on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
8/29/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
CIK
1460602
Fax
N/A
Employees
150
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.36 million
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%
Return on Equity
N/A
Return on Assets
-130.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.07
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$662 thousand
Price / Sales
7.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.58) per share
Price / Book
-0.15

Miscellaneous

Outstanding Shares
4,799,000
Free Float
4,527,000
Market Cap
$4.80 million
Optionable
No Data
Beta
0.44

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners